DOCSLIB.ORG

Pharmcotherapy Update 2012 V 15 Num 4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmcotherapy Update 2012 V 15 Num 4 Volume XV No. IV July/August 2012 Marcia J. Wyman, Pharm.D., BCPS Drug Information Pharmacist Linagliptin: An Alternative Dipeptidyl Peptidase-4 Inhibitor Editor By: Anna Powichrowski, Pharm.D. Mandy C. Leonard, Pharm.D., BCPS System Director, Drug Use Policy and Introduction: Diabetes mellitus affects Food and Drug Administration (FDA) Formulary Management 26 million people in the United States or approved three DPP-4 inhibitors: si- Editor 1 ® about 8.3% of the population. Key risk tagliptin (Januvia ; Merck Company, Meghan K. Lehmann, Pharm.D., BCPS factors for type 2 diabetes include fam- Inc), saxagliptin (Onglyza™; Bristol– Drug Information Specialist ily history, excess weight, lack of regu- Myers Squibb Company), and lina- Editor lar exercise, dyslipidemia, and hyper- gliptin (Tradjenta™; Boehringer tension. 2 Uncontrolled diabetes is asso- Ingelheim Pharmaceuticals, Inc). 4 Amy T. Martin, Pharm.D., BCPS Drug Information Pharmacist ciated with significant morbidity includ- Linagliptan, the newest DPP-4 inhibi- Associate Editor ing chronic kidney disease, retinopathy, tor was approved by the FDA on May neuropathy, amputations, and acute or- 2, 2011. The DPP-4 inhibitors are ap- Marigel Constantiner, MSc, BCPS, CGP, CPh gan failure. Clinical management of proved as an adjunct therapy to diet Drug Information Specialist Associate Editor patients with type 2 diabetes is intended and exercise to improve glycemic to reach and maintain patient-specific control in adults with type 2 diabetes Christopher Snyder, R.Ph. glycemic goals. According to the mellitus. 5-7 Sitagliptin and saxagliptin In this Issue Drug Information Pharmacist American Diabetes Association (ADA), have been evaluated for use as mono- Associate Editor a desirable treatment target for most therapy or in combination with other Katie L. Stabi, Pharm.D., BCPS patients with diabetes is a hemoglobin antidiabetic agents, including met- Drug Information Pharmacist A1C (A1C) level lower than 7%, as long formin and thiazolidinediones when a Associate Editor as the level can be accomplished safely single agent does not provide ade- while minimizing the risk of hypoglyce- quate control. 6,7 In addition, Scott Knoer, MS, Pharm.D., FASHP Chief Pharmacy Officer mia. The American Association of saxagliptin has been evaluated for use Clinical Endocrinologists (AACE) and with sulfonylureas. 7 The ADA ex- In This Issue: American College of Endocrinology cludes DPP-4 inhibitors from the two • Linagliptan Overview (ACE), have a similar A1C target of tiers of preferred agents in their treat- • Formulary Update 6.5% or lower for most patients. 3 First- ment algorithm due to limited data • Frequently Asked Questions 2 line treatment options in type 2 diabetes and high expense of these agents. On involve lifestyle modifications including the other hand, AACE/ACE recom- exercise, meal planning, and weight mends consideration of DPP-4 inhibi- loss. 2,3 However, pharmacotherapy to tors for use with metformin in patients achieve treatment goals is often re- requiring dual therapy especially Drug Information Service (216) 444-6456, option #1 quired. Initial pharmacologic therapy when experiencing hypoglycemia with metformin (Glucophage ®) is rec- and/or weight gain with the other 3 Comprehensive information about ommended, but may not be sufficient to agents. achieve adequate glycemic control. 2,3 medications, biologics, nutrients, and drug therapy Intensification of therapy often involves Mechanism of Action: Linagliptin an addition of an agent from a different inhibits DPP-4, an enzyme that de- Formulary Information pharmacologic class. Dipeptidyl pepti- grades incretin hormones, glucagon- dase-4 (DPP-4) inhibitors are consid- like peptide-1 (GLP-1) and glucose- Medication Inservices ered a reasonable second-line pharma- dependent insulinotropic polypeptide 2,3 5 cologic option after metformin. The (GIP). This activity increases the plasma concentrations of active incretin hormones, thereby stimulating the release of insulin in a glucose-dependent man- ner and decreasing circulating levels of glucagon. Glucagon-like peptide-1 and GIP are involved in physiological regula- tion of glucose homeostasis. Both hormones increase the biosynthesis of insulin and its secretion from pancreatic beta cells in the presence of normal or elevated levels of blood glucose. Glucagon-like peptide-1 also decreases glucagon se- cretion from pancreatic alpha-cells, resulting in a reduction in glucose output from the liver. Pharmacokinetics: Linagliptin has a time to peak concentration following oral administration of 1.5 hours. 5 Its bioavail- ability is 30%. Plasma protein binding is concentration-dependent; however, the percentage of plasma protein binding is not altered in patients with hepatic or renal dysfunction. Its elimination half-life is 12 hours and major route of elimina- tion is enterohepatic excretion as unchanged drug. Select Clinical Trials: Prato and colleagues conducted a trial to investigate the effect of linagliptin monotherapy on gly- cemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes.8 This multicenter, randomized, double-blind trial was conducted between February 15, 2008, and May 6, 2009, at 66 sites in 11 countries. The objective was to investigate the efficacy and safety of linagliptin 5 mg versus placebo administered as monotherapy to patients with type 2 diabetes who were either treatment-naïve or who had received one oral antidiabetic drug. The in- clusion criteria consisted of participants between 18 and 80 years with type 2 diabetes, body mass index (BMI) 2 ≤ 40 kg/m , and with either an A1C of 6.5% to 9.0% and were treated with not more than one antidiabetic agent (excluding thiazolidinediones) or an A1C of 7.0% to 10.0% and were treatment naïve. Key exclusion criteria included participants who had a myocardial infarction, stroke, or transient ischemic attack within 6 months prior to randomization, impaired hepatic function, hypersensitivity to the product, treatment with more than one antidiabetic agent within 10 days, or current treatment with systemic steroids. Prior to study initiation, individuals with an A1C 6.5% to 9.0% had to un- dergo a 6-week washout period of previous antidiabetic medications; afterwards a 2-week placebo run-in period was initi- ated. Treatment-naïve patients with an A1C 7.0% to 10.0% directly entered the 2-week placebo run-in period. An A1C of 7.0% to 10.0% was required by both groups at the start of placebo run-in period. Metformin could be utilized as a res- cue medication only during the randomization period in patients with a confirmed glucose level > 13.3 mmol/L after an overnight fast. Randomization was stratified by A1C < 8.5% versus ≥ 8.5% and by whether or not patients had previously received an oral antidiabetic drug. Following the placebo run-in period, patients were randomized to linagliptin 5 mg once daily or placebo. The primary endpoint was the change from baseline in A1C after 24 weeks. Table 1 contains study outcomes and results. A significantly smaller portion of patients receiving linagliptin required metformin rescue therapy (10.2%) compared with placebo (20.9%) with OR=0.3 (p=0.0002). Overall, 98 patients (58.7%) reported adverse events in the placebo group and 176 patients (52.4%) reported adverse events in the linagliptin group. Mean trough levels of linagliptin over time were comparable between patients with normal renal function and those with mild or moderate renal impairment. Linagliptin dose adjustments may not be required in patients with renal impairment. Both body weight and waist circumference did not differ significantly from baseline in both groups validating that linagliptin is weight neutral. The authors concluded that a clinically relevant reduction in A1C, fasting plasma glucose (FPG), and change in 2-hour postprandial glucose (2h-PPG) from baseline to week 24 were observed with linagliptin compared with placebo. Prato and colleagues conducted a multicenter, randomized, double-blind trial between August 2008 and August 2010 at 53 sites in seven countries. 9 The objective of the trial was to examine the efficacy, safety, and tolerability of linagliptin compared with placebo in patients with type 2 diabetes who were intolerant to metformin therapy or for whom metformin was contraindicated. Participants were included if they were 18 to 80 years of age with type 2 diabetes, BMI ≤ 40 kg/m 2, had intolerability or contraindication to metformin, had an A1C 7.0% to 10.0% and were drug naïve or had an A1C 6.5% to 9.0% and were previously treated with one oral antidiabetic for at least 10 weeks. In order to start in the placebo run-in period patients in both groups needed an A1C of 7.5% to 11.0%. Patients naïve to diabetic treatment directly started in the 2-week placebo run-in period. Select exclusion criteria included those with a myocardial infarction, stroke, or transient ischemic attack within 6 months, impaired hepatic function, severe renal impairment, and treatment with rosiglitazone or pioglitazone, GLP-1 analogs, insulin, or antiobesity drugs in the past 3 months. Following the placebo run-in period, pa- tients were randomized to linagliptin 5 mg once daily or placebo. The primary endpoint was the change from baseline in A1C after 18 weeks. Table 1 contains study outcomes and results. The rate of adverse events was comparable between both groups with 40.4% in the linagliptin group and 48.7% in the placebo group. The mean changes in weight and waist circumference
Load more

Recommended publications
  • Onglyza (Saxagliptin) Uses, Dosage, Side Effects - Drugs.Com 04/07/2015 Insulin Pump – Tubeless Feel the Freedom for Yourself! Learn About the Omnipod®
    Onglyza (saxagliptin) Uses, Dosage, Side Effects - Drugs.com 04/07/2015 Insulin Pump – Tubeless Feel The Freedom For Yourself! Learn About The OmniPod®. Browse all medications A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Advanced Search Phonetic Search Drugs A-Z Pill Identifier Interactions Checker News Health Professionals Q & A Mednotes Apps Home → Conditions → Diabetes, Type 2 → Onglyza Print Share Sign In or Register Onglyza Related Information Availability Pregnancy Category Generic Name: saxagliptin (SAX a GLIP tin) Prescription only No proven risk in Brand Names: Onglyza humans CSA Schedule Not a controlled drug Approval History Drug history at FDA Overview Side Effects Dosage Interactions For Professionals More Reviews Average User Rating Insulin Pump – Tubeless Feel The Freedom For Yourself! Learn About The 9 User Reviews 7.6 Rate it! OmniPod® Drug Class What is Onglyza? Dipeptidyl peptidase 4 inhibitors Onglyza (saxagliptin) is an oral diabetes medicine that helps control blood sugar levels . It works by regulating Related Drugs the levels of insulin your body produces after Diabetes, Type 2 eating. metformin Onglyza is for people with type 2 diabetes. It is insulin aspart Januvia sometimes used in combination with other glipizide diabetes medications, but is not for treating glimepiride type 1 diabetes . Lantus Onglyza may also be used for purposes not Invokana listed in this medication guide. Victoza glyburide Levemir Humalog Actos Important information Janumet You should not use Onglyza if you are in a state of diabetic ketoacidosis (call your doctor for Glucophage treatment with insulin).
    [Show full text]
  • Komboglyze, INN-Saxagliptin, Metformin
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Komboglyze 2.5 mg/850 mg film-coated tablets Komboglyze 2.5 mg/1,000 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Komboglyze 2.5 mg/850 mg film-coated tablets Each tablet contains 2.5 mg of saxagliptin (as hydrochloride) and 850 mg of metformin hydrochloride. Komboglyze 2.5 mg/1,000 mg film-coated tablets Each tablet contains 2.5 mg of saxagliptin (as hydrochloride) and 1,000 mg of metformin hydrochloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Komboglyze 2.5 mg/850 mg film-coated tablets Light brown to brown, biconvex, round, film-coated tablets, with “2.5/850” printed on one side and “4246” printed on the other side, in blue ink. Komboglyze 2.5 mg/1,000 mg film-coated tablets Pale yellow to light yellow, biconvex, oval shaped, film-coated tablets, with “2.5/1000” printed on one side and “4247” printed on the other side, in blue ink. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Komboglyze is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products (see sections 4.4, 4.5 and 5.1 for available data on different combinations) in patients already being treated with the combination of saxagliptin and metformin as separate tablets.
    [Show full text]
  • Reference ID: 3912436 FULL PRESCRIBING INFORMATION
    HIGHLIGHTS OF PRESCRIBING INFORMATION Hypoglycemia: In add-on to sulfonylurea, add-on to insulin, and add-on These highlights do not include all the information needed to use to metformin plus sulfonylurea trials, confirmed hypoglycemia was ONGLYZA safely and effectively. See full prescribing information for more common in patients treated with ONGLYZA compared to placebo. ONGLYZA. When used with an insulin secretagogue (e.g., sulfonylurea) or insulin, a lower dose of insulin secretagogue or insulin may be required to ONGLYZA (saxagliptin) tablets, for oral use minimize the risk of hypoglycemia. (5.3, 6.1) Initial U.S. Approval: 2009 Hypersensitivity-Related Events (e.g., urticaria, facial edema): More common in patients treated with ONGLYZA than in patients treated -------------------------- RECENT MAJOR CHANGES -------------------------- with placebo; and postmarketing reports of serious hypersensitivity Warnings and Precautions reactions such as anaphylaxis, angioedema, and exfoliative skin Pancreatitis (5.1) 4/2016 conditions. Promptly discontinue ONGLYZA, assess for other potential Heart Failure (5.2) 4/2016 causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. (5.4, 6.1, 6.2) --------------------------- INDICATIONS AND USAGE -------------------------- Arthralgia: Severe and disabling arthralgia has been reported in patients ONGLYZA is a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an taking DPP4 inhibitors. Consider as a possible cause for severe joint adjunct to diet and exercise to improve glycemic control in adults with type 2 pain and discontinue drug if appropriate. (5.5) diabetes mellitus. (1.1, 14) Macrovascular Outcomes: There have been no clinical studies Limitation of use: establishing conclusive evidence of macrovascular risk reduction with Not used for the treatment of type 1 diabetes mellitus or diabetic ONGLYZA or any other antidiabetic drug.
    [Show full text]
  • KOMBIGLYZE XR Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------WARNINGS AND PRECAUTIONS----------------------- These highlights do not include all the information needed to use Lactic acidosis: Warn patients against excessive alcohol intake. KOMBIGLYZE XR safely and effectively. See full prescribing KOMBIGLYZE XR not recommended in hepatic impairment and information for KOMBIGLYZE XR. contraindicated in renal impairment. Ensure normal renal function KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release) before initiating and at least annually thereafter. Temporarily tablets discontinue KOMBIGLYZE XR in patients undergoing radiologic Initial U.S. Approval: 2010 studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and WARNING: LACTIC ACIDOSIS fluids. (4, 5.1, 5.3, 5.4, 5.7, 5.10, 5.11) See full prescribing information for complete boxed warning. There have been postmarketing reports of acute pancreatitis in patients Lactic acidosis can occur due to metformin accumulation. The taking saxagliptin. If pancreatitis is suspected, promptly discontinue risk increases with conditions such as sepsis, dehydration, excess KOMBIGLYZE XR. (5.2) alcohol intake, hepatic impairment, renal impairment, and acute Vitamin B12 deficiency: Metformin may lower vitamin B12 levels. congestive heart failure. (5.1) Measure hematological parameters annually. (5.5, 6.1) Symptoms include malaise, myalgias, respiratory distress, Hypoglycemia: When used with an insulin
    [Show full text]
  • Saxagliptin / Metformin Hcl Extended-Release) Tablets
    For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only (Saxagliptin / Metformin HCl extended-release) tablets. KOMBIGLYZETM XR Abbreviated Prescribing Information INDICATIONS AND USAGE: KombiglyzeTM XR is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. IMPORTANT LIMITATIONS OF USE: KombiglyzeTM XR should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis; it has not been studied in patients with a history of pancreatitis. DOSAGE AND ADMINISTRATION: Generally should be administered once daily with the evening meal, with gradual dose titration to reduce the gastrointestinal side effects associated with metformin. • The recommended starting dose in patients who need 5 mg of saxagliptin and who are not currently treated with metformin is 5 mg saxagliptin/500 mg metformin extended-release. In patients treated with metformin, the dose should provide metformin at the dose already being taken, or the nearest therapeutically appropriate dose. • Patients who need 2.5 mg saxagliptin in combination with metformin extended-release may be treated with KombiglyzeTM XR 2.5 mg/1000 mg. • The maximum daily recommended dose is 5 mg for saxagliptin and 2000 mg for metformin extended-release. When co-administered with strong CYP3A4/5 inhibitors, limit the dose to 2.5 mg/1000 mg once daily. • When KOMBIGLYZETM XR is used in combination with an insulin secretagogue (e.g. sulphonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to minimise the risk of hypoglycaemia.
    [Show full text]
  • Linagliptin (Tradjenta) for the Treatment of Diabetes Mellitus KAREN WHALEN, Pharmd, BCPS, CDE, and KAREN R
    STEPS New Drug Reviews Linagliptin (Tradjenta) for the Treatment of Diabetes Mellitus KAREN WHALEN, PharmD, BCPS, CDE, and KAREN R. SANDO, PharmD, CDE University of Florida College of Pharmacy, Gainesville, Florida STEPS new drug reviews Linagliptin (Tradjenta) is a dipeptidyl-peptidase-4 (DPP-4) inhibitor labeled for the treat- cover Safety, Tolerability, ment of type 2 diabetes mellitus. Similar to sitagliptin (Januvia) and saxagliptin (Onglyza), Effectiveness, Price, and Simplicity. Each indepen- linagliptin delays the breakdown of endogenous incretin hormones such as glucagon-like dent review is provided peptide 1 and glucose-dependent insulinotropic polypeptide. These hormones, when secreted by authors who have no in response to food intake, stimulate postmeal insulin secretion, inhibit glucagon release, financial association with improve satiety, and slow gastric emptying.1,2 Linagliptin can be used alone or in combination the drug manufacturer. with metformin (Glucophage), sulfonylureas, pioglitazone (Actos), or insulin. The series coordinator for AFP is Allen F. Shaugh- nessy, PharmD, Tufts Drug Dosage Dose form Cost* University Family Medicine Residency Program at Linagliptin (Tradjenta) 5 mg daily 5-mg tablet $254 for 30 tablets Cambridge Health Alli- ance, Malden, Mass. *—Estimated retail price of one month’s treatment based on information obtained at http://www.goodrx.com A collection of STEPS pub- (accessed October 1, 2012). lished in AFP is available at http://www.aafp.org/ afp/steps. SAFETY control should be used in patients receiving Few severe adverse effects have been associ- strong inducers of cytochrome P450 3A4 ated with linagliptin. When used alone or or P-glycoprotein, such as rifampin. Lina- with metformin or pioglitazone, linagliptin gliptin is a U.S.
    [Show full text]
  • Dapagliflozin Plus Saxagliptin Add-On Therapy Compared with Insulin In
    EMERGING THERAPIES: DRUGS AND REGIMENS Diabetes Care 1 fl Tina Vilsbøll,1 Ella Ekholm,2 Eva Johnsson,2 Dapagli ozin Plus Saxagliptin Nalina Dronamraju,3 Serge Jabbour,4 and Add-on Therapy Compared With Marcus Lind5 Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial https://doi.org/10.2337/dc18-1988 OBJECTIVE This study evaluated whether an oral combination of a sodium–glucose cotrans- porter 2 inhibitor and a dipeptidyl peptidase 4 inhibitor achieved glycemic control similar to basal insulin in patients with type 2 diabetes, poorly controlled with metformin, without increasing hypoglycemia or body weight. RESEARCH DESIGN AND METHODS In a multinational, open-label, randomized, phase 3 trial (NCT02551874), adults with type 2 diabetes inadequately controlled on metformin, with or without sulfonyl- urea, were randomized (1:1) to receive dapagliflozin (DAPA) plus saxagliptin (SAXA) or titrated insulin glargine (INS). The primary end point was change in glycated hemoglobin A1c (HbA1c) from baseline to week 24. DAPA + SAXA treatment was tested for noninferiority versus INS. 1Steno Diabetes Center Copenhagen, University of Copenhagen, Copenhagen, Denmark 2 RESULTS AstraZeneca Gothenburg, Molndal,¨ Sweden 3 fi 6 6 6 AstraZeneca, Gaithersburg, MD The ef cacy data set included 643 patients (mean SD HbA1c, 9.1 1.0% [75 4Division of Endocrinology, Thomas Jefferson 11 mmol/mol]). At week 24, DAPA + SAXA treatment versus INS resulted in University Hospital, Philadelphia, PA 5Institute of Medicine, University of Gothenburg, noninferior reductions in HbA1c (adjusted mean 6 SE change, 21.7 6 0.1% vs. 21.5 6 0.1% [18.3 6 0.7 mmol/mol vs.
    [Show full text]
  • Saxagliptin and Alogliptin
    Saxagliptin and Alogliptin – New Warnings • On April 5, 2016, the FDA announced that type 2 diabetes medicines containing AstraZeneca’s saxagliptin and Takeda’s alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. Consequently, the FDA has added new warnings to the Warnings and Precautions section of the drug labels regarding this safety issue. — Currently available saxagliptin and alogliptin products include: Onglyza® (saxagliptin), Kombiglyze® XR (saxagliptin/metformin extended-release), Nesina® (alogliptin), Kazano™ (alogliptin/metformin), and Oseni™ (alogliptin/pioglitazone). • Saxagliptin and alogliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors, both indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. — Saxagliptin and alogliptin should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. — Oseni should be used with caution in patients with liver disease. • The safety update is based on two large cardiovascular outcomes trials (CVOT) conducted in patients with heart disease. — These clinical trials were also discussed at the FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting in April 2015. — In both trials, it was noted that more patients who received saxagliptin- or alogliptin-containing medications were hospitalized for heart failure compared with placebo. — In the saxagliptin trial, 3.5% of patients who received saxagliptin were hospitalized for heart failure vs. 2.8% of patients who received placebo. — In the alogliptin trial, 3.9% of patients treated with alogliptin were hospitalized for heart failure vs. 3.3% of patients who received placebo. • Patients should be informed of the signs of heart failure and should talk to their healthcare professional if they experience symptoms such as unusual shortness of breath during daily activities; trouble breathing when lying down; tiredness, weakness, or fatigue; and weight gain with swelling in the ankles, feet, legs or stomach.
    [Show full text]
  • Is the Use of DPP-4 Inhibitors Associated with an Increased Risk for Heart Failure?
    S210 Diabetes Care Volume 39, Supplement 2, August 2016 Is the Use of DPP-4 Inhibitors Guntram Schernthaner,1 Avivit Cahn,2 and Itamar Raz2 RECENT OUTCOME STUDIES Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS Diabetes Care 2016;39(Suppl. 2):S210–S218 | DOI: 10.2337/dcS15-3009 About 40 years ago, the Framingham study first documented that the risk for heart failure (HF) in patients with diabetes was about twofold higher in men and fivefold in women compared with individuals without diabetes (1). The UK Prospective Di- abetes Study (UKPDS) reported that the incidence of hospital admission for HF was similar to that of nonfatal myocardial infarction and nonfatal stroke (2). A more recent 6-year follow-up study of 65,619 patients with type 2 diabetes treated with insulin reported that the hospital admission rate due to HF (243 of 10,000) was higher than that due to myocardial infarction (97 of 10,000) or stroke (151 of 10,000) (3). The pathogenesis of HF in diabetes is multifactorial but can largely be attributed to four key factors: coronary artery disease (CAD), hypertension, diabetic cardio- myopathy, and extracellular fluid volume expansion (4,5). Remarkably, type 2 di- abetes itself is a recognized risk factor for HF, independent of CAD and hypertension (4), suggesting that glycemic control may influence the development of HF. Hyper- glycemia can exert deleterious effects on the myocardium and has been shown to increase oxidative stress, promote accumulation of advanced glycation end prod- ucts, and cause interstitial fibrosis (6).
    [Show full text]
  • Type I Diabetes Treatments Clinical Notes Recommendations
    Ramsell's Recommendation: NV ADAP should cover Diabetic Supplies such as Lancets, test strips, needles ONLY. Diabetic Meters in most cases are obtained free of charge to patients or thru patient assistance programs. Recommendations (Use DM TXT guidelines and for efficient treatment recommendations. X Consider effiacacy, safety, and cost combined with a patient-centered approach when choosing Type I Diabetes Treatments Clinical notes formulary/TXT agents. NV Medicaid Questions? For Type 1 and some cases of Type 2 DM, ADD ALL Insulins INSULINS Vials & Pens Short Acting Insulins regular insulin (Humulin and Novolin) √ Rapid Acting Insulins insulin aspart(NovoLog, FlexPen) √ insulin glulisine (Apidra) √ insulin lispro (Humalog) √ Intermediate Acting Insulins insulin isophane (Humulin N, Novolin N) √ Long Acting Insulins insulin degludec (Tresiba) √ insulin detemir (Levemir) √ insulin glargine (Lantus) √ insulin glargine (Toujeo) Combination Insulins NovoLog Mix 70/30 (insulin aspart protamine-insulin aspart) Humalog Mix 75/25 (insulin lispro protamine-insulin lispro) Humalog Mix 50/50 (insulin lispro protamine-insulin lispro) Humulin 70/30 (human insulin NPH-human insulin regular) Novolin 70/30 (human insulin NPH-human insulin regular) Ryzodeg (insulin degludec-insulin aspart) Amylinomimetic Drug Pramlintide (SymlinPen 120, SymlinPen 60) √ Consider efficacy, safety, and cost combined with a patient- centered approach when Type 2 Diabetes Treatments choosing agents. These drugs slow the digestion of starches and sugars and are used for mild Alpha-glucosidase inhibitor cases of diabetes acarbose (Precose) √ miglitol (Glyset) √ Metformin is the preferred first-line agent providing a 1-2% decrease in A1c. • Metformin is not associated with weight gain, has a low risk for hypoglycemia, and is the most cost effective agent.
    [Show full text]
  • Understanding Your Diabetes Medicines DRUG CLASS
    Understanding Your Diabetes Medicines DRUG CLASS: Alpha-Glucosidase Inhibitors Brand NAME Generic Name Precose Acarbose Glyset Miglitol HOW DOES IT WORK? • Slows down the breakdown of carbohydrates in the intestines (gut). • This helps slow down the rise in blood sugar after a meal. WHEN DO YOU TAKE THIS MEDICINE? • With the FIRST BITE of food at each main meal. COMMON SIDE EFFECTS: • Gas, bloating, belly pain, diarrhea o Sometimes a lower dose and increasing the dose slowly will help decrease gas. o These side effects may decrease over time. • Does not cause low blood sugar if taken alone, if they are not used with other medications that can cause low blood sugar. SPECIAL TIPS: • Because they slow down the absorption of carbohydrates, if treating a low blood sugar, pure glucose like gel or tablets work best • Taken medication with FIRST BITE of food for each main meal. • Take with a full glass of water (Glyset). • If you skip a meal, skip the medication. • Low blood sugar must be treated with glucose tables, gel or milk. • Not recommended for people with any kind of bowel problems like ulcerative colitis or diverticulitis. Kentucky Diabetes Prevention and Control Program 2021 This content is for general reference to this medication and is not intended to replace the manufacturer product information or prescriber’s guidance. Understanding Your Diabetes Medicines DRUG CLASS: Amylin Mimetic BRAND NAME GENERIC NAME Symlin Pramlintide HOW DOES IT WORK? Symlin works by slowing down food digestion. This helps the blood sugar rise more slowly after eating.It may also help you feel full faster.
    [Show full text]
  • ACCEPTABLE COMBINATIONS of DIABETES MEDICATIONS (Updated 01/27/2021)
    ACCEPTABLE COMBINATIONS OF DIABETES MEDICATIONS (Updated 01/27/2021) The chart on the following page outlines acceptable combinations of medications for treatment of diabetes. Please note: • Initial certification of all applicants with diabetes mellitus (DM) requires FAA decision; • Use no more than one medication from each group (A-F); • Fixed-dose combination medications - count each component as an individual medication. (e.g., Avandamet [rosiglitazone + metformin] is considered 2-drug components); • Up to 3 medications total are considered acceptable for routine treatment according to generally accepted standards of care for diabetes (American Diabetes Association, American Association of Clinical Endocrinologists); • For applicants receiving complex care (e.g., 4-drug therapy), refer the case to AMCD; • For applicants on AASI for diabetes mellitus, follow the AASI; • Consult with FAA for any medications not on listed on the chart; • Observation times: When initiating NEW diabetes therapy using monotherapy or combination medications: Adding Medication Observation Time Group A ONLY 14 days Group B-D 30 days Group E1 60 days When ADDING a new medication to an ESTABLISHED TREATMENT regimen: Current Medication Adding Medication Observation Time on Group A-D + new Group A-D 14 days on Group E1 + new Group A-D 30 days on Group A-D + new Group E1 60 days Note: If transitioning between injectable GLP-1 RA and oral GLP-1 RA formulation = 72 hours When initiating NEW or ADDING therapy for any regimen (new or established therapy): Adding Medication Observation Time Group F (SGLT2 inhibitors) 90 days Group E2 (insulin): • For agency ATCSs (non-CGM or CGM protocol) 90 days • For Pilots / Part 67 applicants, class 3 non-CGM 90 days protocol only: 180 days • For Pilots / Part 67 applicants, any class CGM protocol: ACCEPTABLE COMBINATIONS OF DIABETES MEDICATIONS (Updated 01/27/2021) Biguanides A -metformin (e.g.
    [Show full text]